NovoCure presents positive phase 3 LUNAR trial results for TTFields in NSCLC at ASCO

NovoCure Ltd

Positive results from phase 3 LUNAR trial of TTFields plus standard therapies for NSCLC announced at ASCO 2023.
Data presented on June 6, 2023; filing does not disclose specific efficacy or safety metrics.
Company intends to discuss regulatory submission for potential NSCLC indication expansion.
Ticker NVCR; positive clinical milestone for TTFields therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.